Bli medlem
Bli medlem

Du är här

2014-04-29

Recipharm AB: Recipharm appoints new Directors, Business Management to further strengthen European sales drive

29th April: Recipharm, the leading contract development and
manufacturing organisation, is pleased to announce the appointment of
two new Directors of Business Management. These appointments form
part of Recipharm's strategic drive to increase the volume of its
business and revenues in key European markets.

Henning Neubauer has joined the Business Management team at Recipharm,
taking on the position of Business Director for Northern Germany and
the Netherlands. In parallel, Antonio Lopez also joins the team in
the role of Business Director for Spain and Southern France.

Previously, Neubauer was Chief Operating Officer (COO). at a German
start-up company in Hamburg dealing with generic products, OTC and
Rx. Prior to that, he worked for more than ten years at Haupt Pharma
as Head of Customer Service and Sales, responsible for leading the
Customer Service Team and key account management. He has a degree and
Diploma in Marketing from the Open University of Bad Harzburg.

Antonio Lopez, has previous experiences in Business Development and
partnering, logistics, compliance and regulatory activities in the
role as VP of Operations in Flavine, a US trading company involved in
generics APIs and finished dosage forms. Prior to this, he worked for
more than 20 years at the Spanish pharmaceutical company Grupo
Uriach. Antonio graduated with a Pharmacist degree from the
University of Barcelona and holds a Masters in Business
Administration from Barcelona's Esade Business School.

As a further initiative to bolster the Business Management
organization, Åsa Wilander joined the team in mid-January in the new
role of Key Account Director for the Nordic region. In this role,
Åsa will be responsible for coordinating customer management and
commercial aspects, as well as developing relationships with a
selected number of customers. Åsa has been with Recipharm since 2007.
To date, she has been working as General Manager of the Höganäs
facility and led a significant expansion of the company. She has some
30 years experience of the pharmaceutical industry including the
leadership of a contract manufacturing supply team at Pfizer.

Commenting on the new appointments, Kenth Berg, VP Business Management
Recipharm, stated: "I am very pleased to have such talent join our
business management structure. Europe is one of our key markets and
we look forward to utilising the respective skills and expertise of
Henning and Antonio to further enhance our European sales drive in
Germany, the Netherlands and Spain."

He continued: "Indeed post our recent IPO, this is an exciting time to
plan ahead and expand our revenues and turnover across our
international operations of which Europe is a highly important
component".

Contact information
Recipharm - Kenth Berg, Vice Presidens Business Management, Contact:
+46 8 602 52 16

For media enquiries, please contact Tristan Jervis or Alex Heeley at
De Facto Communications on: E-mail: t.jervis@defacto.com or
a.heeley@defacto.com

Tel: +44 (0) 207 861 3019/3043
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden
employing some 1,500 employees. Recipharm offers manufacturing
services of pharmaceuticals in various dosage forms, production of
clinical trial material and pharmaceutical product development.
Recipharm currently manufactures more than 200 different products to
both Big Pharma and smaller research- and development companies.
Recipharm's turnover is approximately SEK 2.1 billion and the Company
operates development and manufacturing facilities in Sweden, France,
the UK, Germany and Spain and is headquartered in Jordbro.

-----------------------------------------------------------
http://news.cision.com/recipharm-ab/r/recipharm-appoints-new-directors--...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.